Abstract 98P
Background
Aumolertinib as a novel third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) has been shown to be efficacy in EGFR mutations and also in CNS metastasis NSCLC. We aimed to evaluate long-term efficacy and safety of adjuvant aumolertinib in postoperative patients.
Methods
A total of 215 patients who underwent radical lung cancer surgery with EGFR-sensitizing mutations from four different medical centers were enrolled and received aumolertinib 110 mg daily, the medication time (6months-36months) depended on the pathological stage and physical conditions. The disease-free survival (DFS), safety and tolerability were evaluated.
Results
The study retrospectively analyzed 215 patients with pathologically confirmed adenocarcinoma, EGFR mutation-positive, stage Ia2–Ⅲa NSCLC (132 females, 87 males, ranging in age from 27 to 86 years, with a median age of 63). All patients were followed for at least 6 months, 40 patients have been followed up for over 2 years, and 110 patients have been followed for over 1 year. At data cutoff, all patients were alive, only one patient had bone metastasis, and no patient presented with CNS metastasis. 2-year DFS was 99%. During aumolertinib treatment, 69 patients (69/215, 32.1%) experienced drug-related adverse reactions. Rash (39/215, 18.1%), diarrhea (15/215, 7.0%), abnormal liver and kidney function (12/215, 5.6%), and mouse ulcer (11/215, 5.1%). There was no grade ≥3 adverse events that occurred, and no patients withdrew from treatment due to adverse reactions.
Conclusions
Based on our previous study, we expanded the number of patients and extended the follow-up period. Our study further demonstrates the pronounced efficacy of aumolertinib in the postoperative adjuvant treatment of NSCLC with an excellent safety profile. Long term follow-up of our study is ongoing to investigate further survival outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Zhang: Financial Interests, Personal, Sponsor/Funding: Hansoh Pharma.
All other authors have declared no conflicts of interest.